| Not Yet Recruiting | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Conge Congenital Adrenal Hyperplasia | Phase 2 | 2026-04-01 |
| Recruiting | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Schizophrenia | Phase 2 | 2026-02-16 |
| Not Yet Recruiting | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia Tardive Dyskinesia | Phase 2 | 2026-01-01 |
| Recruiting | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Bipolar I Disorder, Mania | Phase 2 | 2025-12-24 |
| Recruiting | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Schizophrenia | Phase 3 | 2025-12-16 |
| Recruiting | Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia | Phase 2 | 2025-09-30 |
| Recruiting | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Re Schizophrenia, Schizoaffective Disorder, Bipolar Disorder | Phase 4 | 2025-08-29 |
| Recruiting | A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Majo Major Depressive Disorder | Phase 3 | 2025-08-18 |
| Recruiting | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia | Phase 3 | 2025-08-11 |
| Recruiting | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia Schizophrenia | Phase 3 | 2025-07-11 |
| Recruiting | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Part Major Depressive Disorder | Phase 3 | 2025-05-30 |
| Recruiting | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Schizophrenia | Phase 3 | 2025-05-08 |
| Recruiting | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participant Major Depressive Disorder | Phase 3 | 2025-04-16 |
| Recruiting | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Part Major Depressive Disorder | Phase 3 | 2025-03-31 |
| Recruiting | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major D Major Depressive Disorder | Phase 3 | 2025-01-22 |
| Enrolling By Invitation | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Chorea, Huntington | Phase 3 | 2024-04-24 |
| Completed | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder Major Depressive Disorder | Phase 2 | 2024-03-20 |
| Completed | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tar Schizophrenia, Schizoaffective Disorder, Bipolar Disorder | Phase 4 | 2023-05-09 |
| Terminated | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizop Schizophrenia | Phase 3 | 2023-01-05 |
| Terminated | Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications Focal Onset Seizure, Focal Onset Epilepsy | Phase 2 | 2022-11-09 |
| Completed | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Schizophrenia | Phase 2 | 2022-10-04 |
| Active Not Recruiting | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants Wit SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | 2022-07-12 |
| Terminated | Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | Phase 2 | 2022-06-07 |
| Active Not Recruiting | Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to C Dyskinesia, Cerebral Palsy | Phase 3 | 2022-04-15 |
| Completed | Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) Major Depressive Disorder | Phase 2 | 2022-02-21 |
| Terminated | Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephal SCN8A Developmental and Epileptic Encephalopathy Syndrome | Phase 2 | 2022-01-31 |
| Terminated | Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impair Schizophrenia | Phase 2 | 2021-12-07 |
| Completed | Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD Anhedonia, Major Depressive Disorder | Phase 2 | 2021-11-30 |
| Completed | Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schi Schizophrenia | Phase 3 | 2021-11-29 |
| Completed | A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Me Focal Onset Seizure, Focal Onset Epilepsy | Phase 2 | 2021-11-08 |
| Active Not Recruiting | Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenita Congenital Adrenal Hyperplasia | Phase 3 | 2021-06-25 |
| Completed | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Enceph Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | Phase 2 | 2021-04-26 |
| Completed | Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor Essential Tremor | Phase 2 | 2021-04-20 |
| Completed | Opicapone Treatment Initiation Open-Label Study Parkinson Disease | — | 2021-03-01 |
| Active Not Recruiting | Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia | Phase 3 | 2020-12-16 |
| Active Not Recruiting | Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated Wit Chorea, Huntington | Phase 3 | 2020-09-18 |
| Completed | A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics Healthy Volunteers | Phase 1 | 2020-02-17 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Particip CAH - Congenital Adrenal Hyperplasia | Phase 2 | 2019-12-12 |
| Completed | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disea Chorea, Huntington | Phase 3 | 2019-11-13 |
| Completed | Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Tardive Dyskinesia (TD) | Phase 4 | 2019-03-18 |
| Completed | A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants U Healthy Volunteers | Phase 1 | 2019-02-11 |
| Completed | A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Hea Healthy Volunteers | Phase 1 | 2018-10-18 |
| Terminated | Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome Tourette Syndrome | Phase 2 | 2018-10-17 |
| Completed | VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) Parkinson's Disease | Phase 1 | 2018-10-17 |
| Completed | Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects Healthy Volunteers | Phase 1 | 2018-10-09 |
| Completed | The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Tardive Dyskinesia (TD) | Phase 4 | 2018-09-14 |
| Completed | Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies Parkinson's Disease | — | 2018-08-24 |
| Terminated | Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Tourette Syndrome | Phase 2 | 2018-04-17 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hy CAH - Congenital Adrenal Hyperplasia | Phase 2 | 2018-04-10 |
| Completed | A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Diseas Parkinson Disease | Phase 1 | 2018-02-08 |
| Completed | Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Sy Tourette Syndrome | Phase 2 | 2018-02-08 |
| Completed | A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia Schizophrenia | Phase 2 | 2018-01-10 |
| Completed | A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia Schizophrenia | Phase 2 | 2018-01-04 |
| Completed | A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Stable Schizophrenia | Phase 2 | 2017-12-21 |
| Completed | Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxi Friedreich Ataxia | Phase 2 | 2017-11-08 |
| Completed | Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Tourette Syndrome | Phase 2 | 2017-10-05 |
| Completed | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Heal Healthy | Phase 1 | 2017-07-21 |
| Completed | Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease | Phase 1 | 2017-05-11 |
| Completed | A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation Healthy Volunteers | Phase 1 | 2017-04-04 |
| Unknown | Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Tardive Dyskinesia | — | 2017-04-04 |
| Completed | A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induc Healthy Volunteers | Phase 1 | 2016-12-05 |
| Completed | Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Tourette Syndrome | Phase 2 | 2016-07-25 |
| Completed | Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Tardive Dyskinesia | Phase 3 | 2016-06-13 |
| Completed | Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study Healthy Volunteers, Schizophrenia | Phase 1 | 2016-05-09 |
| Completed | Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Tourette Syndrome | Phase 2 | 2016-03-23 |
| Completed | Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administratio Healthy | Phase 1 | 2016-03-21 |
| Completed | Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Tourette Syndrome | Phase 2 | 2015-11-01 |
| Terminated | A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants Schizophrenia, Cerebellar Ataxia | Phase 1 | 2015-09-23 |
| Completed | TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants Depressive Disorder | Phase 1 | 2015-08-26 |
| Completed | Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Tardive Dyskinesia | Phase 3 | 2015-03-01 |
| Withdrawn | Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyper Congenital Adrenal Hyperplasia | Phase 1 | 2015-02-01 |
| Completed | A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Tardive Dyskinesia | Phase 3 | 2014-10-01 |
| Completed | Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome Tourette Syndrome | Phase 1 | 2014-09-01 |
| Completed | Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease Parkinson's Disease | Phase 1 | 2013-10-01 |
| Completed | Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Se Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects | Phase 1 | 2013-08-01 |
| Completed | Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects | Phase 1 | 2013-07-01 |
| Completed | NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Tardive Dyskinesia | Phase 2 | 2012-12-01 |
| Completed | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder ( Tardive Dyskinesia | Phase 2 | 2012-09-01 |
| Completed | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Tardive Dyskinesia | Phase 2 | 2011-08-01 |
| Completed | Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Tardive Dyskinesia | Phase 2 | 2011-01-01 |
| Withdrawn | An Exploratory Study of NBI-34060 Capsules and Next Day Functioning Insomnia | Phase 3 | 2007-09-01 |
| Terminated | Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression Insomnia, Depression | Phase 3 | 2005-11-01 |
| Completed | Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) Multiple Sclerosis | Phase 2 | 2003-07-01 |
| Completed | Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Breast Cancer, Kidney Cancer, Lung Cancer | Phase 1 | 2002-01-01 |
| Completed | A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | Phase 1 | 2001-12-01 |
| Completed | NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme Brain and Central Nervous System Tumors | Phase 2 | 2001-03-01 |